HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare demonstrated strong financial flexibility by ending the year with $1.04 billion in cash and $5.78 billion available under credit facilities, alongside an 8.3% increase in its dividend to $0.78 per share. The company's expected EBITDA growth of 7.6% at the mid-point, coupled with an improvement in EBITDA margins by 60 basis points, reflects effective management strategies and robust operational performance. Additionally, continued investments in high-acuity programs and increased capital expenditures of $5.0 to $5.5 billion for 2026 indicate HCA's commitment to expanding its network and enhancing inpatient capacity.

HCA Healthcare is facing significant challenges that cast a negative outlook on its financial performance, notably a decline in same-store revenue per adjusted admission, which fell to +2.9%, below expectations of +3.8% and consensus of +4.0%. The firm anticipates a 30% decline in the utilization of care for uninsured patients, along with a projected $250-$450 million decline in DPP net benefits due to changes in Medicaid programs and the reversal of prior benefits. Furthermore, the expected Adjusted EBITDA for 2026 of $15.55-$16.45 billion reflects pressures from declining revenues and decreased service utilization that are likely to impact overall profitability.